Abstract Why and how HIV makes people sick is highly debated.
Introduction
HIV infection is characterized by a progressive immunodeficiency, which is reflected in a steady decline of CD4+ T cells. Disease progression varies considerably from patient to patient. Some develop the acquired immunodeficiency syndrome (AIDS) after a few months; others remain healthy for decades. Such a disparity also exists in monkeys of distinct species infected with simian immunodeficiency virus (SIV). SIV infection of African monkeys, the natural hosts for SIV, does not result in simian AIDS, but SIV infection of most Asian monkeys rapidly progresses to AIDS [43] . Remarkably, despite 25 years of HIV and SIV research, the reasons for these differences in disease outcome are only partially understood. To design new treatment approaches, including vaccination or eradication strategies, we need to understand the basis for these disparities.
Immune dysfunction and disease onset cannot be explained solely by the direct cytopathic effect of the virus. Other factors have been implicated in T cell loss, such as the killing of infected cells by cytotoxic T cells, bystander death of uninfected cells due to HIV products, and T cell dysfunction and death due to heightened levels of immune activation [52] . A hyperactive immune state with high T cell turnover, polyclonal activation of B cells, and elevated proinflammatory cytokines is characteristic of HIV infection [52] . In fact, the activation status of CD8+ T cells is one of the best predictors of disease progression [28] . While the association of immune activation and HIV infection is well known, its causes are only partially understood.
A recent model links disturbance of the gut-associated lymphoid tissue (GALT) to immune activation and lentiviral disease progression [6] . The GALT is one of the primary organs affected by HIV and SIV, and GALT lymphocytes are the primary target cells of HIV during mucosal transmission. After rectal exposure, they are the first immune cells that encounter HIV. For infections by different routes, they form a large pool of HIV target cells, in which HIV efficiently spreads and replicates. Later on, during chronic HIV infection, loss of GALT integrity may have a major impact on AIDS pathogenesis [40] . Briefly, during the chronic phase of infection, elevated levels of microbial products are found in the systemic circulation, and these levels correlate with immune activation and disease state. Initial studies looking at interactions of lentiviruses with the GALT focused mainly on numbers of infected and dying T cells. Recently, studies have proposed cellular and molecular mechanisms that clarify the intricate role of GALT in HIV pathogenesis. Here, we will review these studies and relate their findings to lentiviral disease progression.
Profound depletion of GALT lymphocytes occurs during acute lentiviral infection
The CD4+ T cell count in the blood is a commonly used clinical marker for monitoring progression rate in HIV infection. In acute HIV infection, blood CD4+ T cell numbers may decline sharply, but as soon as an antiviral immune response is established, blood CD4+ T cells have the potential to recover. Subsequently, during chronic HIV infection, blood CD4+ T cell counts decline slowly, but this loss can be partially reversed by successful antiretroviral treatment. However, T cells in the GALT display entirely different kinetics: in SIV-infected macaques and in HIVinfected humans, CD4+ T cells of the lamina propria are rapidly and profoundly depleted in the first days after infection, and their numbers remain low throughout the course of disease [34, 51, 54] . Even after years of antiretroviral therapy, this loss is only partially reversible in most patients [17, 35] . Thus, lymphocyte depletion in the GALT is a distinct feature of lentiviral infection.
The pronounced loss of GALT lymphocytes probably occurs because the majority of newly transmitted HIV strains use CCR5 as a coreceptor for cell entry [2] . A high percentage of CD4+ T cells in the intestinal effector sites are CCR5-positive memory cells, and, thus, GALT lymphocytes are ideal viral targets. In contrast, many T cells in blood and lymph nodes are naive and hence CCR5 negative [41] . During acute SIV infection, up to 60% of all memory CD4+ T cells in the jejunum harbor HIV DNA [33] , suggesting that direct viral cytopathic effects cause the massive loss of CD4+ T cells during acute infection. Furthermore, high levels of Fas-mediated apoptosis of infected and uninfected CD4+ T cells occur during peak viremia [26] . Direct viral killing and bystander death of uninfected cells wipe out most of the CD4+ memory cell population in the GALT.
When the loss of GALT lymphocytes was first discovered, it appeared plausible that this defect in mucosal immune surveillance would have dire consequences for the whole immune system and would influence disease progression. Surprisingly, however, SIV depletes lamina propria T cells in all monkey species, irrespective of whether they will develop simian AIDS or not. Natural SIV hosts, such as sooty mangabeys and African green monkeys, do not progress to AIDS despite high viral loads, but rhesus macaques infected with the same SIV strain show blood CD4+ T cell loss and disease progression, closely resembling HIV pathogenesis in humans [43] . In both the pathogenic and nonpathogenic SIV model, GALT CD4+ T cells are lost at similar rates during acute infection [15, 42] . At later times, however, the GALT can be partially restored in the nonpathogenic models. These observations indicate that acute intestinal CD4+ T cell loss is a basic feature of lentiviral infections but is not predictive of later disease outcome. Low numbers of GALT lymphocytes per se do not make animals or humans sick; additional factors are important for the pathogenic potential of HIV.
In chronic lentiviral infection, circulating microbial products are associated with immune activation Differences in pathogenic and nonpathogenic SIV models become more apparent when GALT function, rather than simple lymphocyte numbers, is considered. The GALT prevents microbial invasions from the intestinal lumen. In chronic lentiviral infections, this function seems to be disturbed, and more microbial products are found in the systemic circulation.
Brenchely et al. [7] measured plasma levels of lipopolysaccharide (LPS), a component of gramnegative bacterial cell walls, as an indicator of microbial translocation from the gut. They found higher plasma LPS levels in chronically HIV-infected patients than in healthy subjects. Notably, a similar LPS increase was observed in the pathogenic SIV rhesus macaque model. In contrast, in the nonpathogenic SIV sooty mangabey model, LPS levels were low, irrespective of SIV status. Thus, in SIV-infected sooty mangabeys, GALT immune function appears to be sufficient to prevent increases of bacterial products in the systemic circulation despite intestinal CD4+ T cell depletion.
To further elucidate the connection between clinical outcome and microbial translocation, plasma LPS levels were examined in defined subsets of patients. For example, Hunt et al. [21] verified a finding from Brenchely et al. [7] : HIV-infected elite controllers-patients with undetectable viral loads without antiretroviral treatment-have LPS levels similar to patients with higher viral loads. At first glance, these data might indicate that no connection between plasma LPS and disease outcome exists. However, Hunt et al. showed that plasma LPS in elite controllers correlated with immune activation, which was associated with lower CD4+ T cell counts. This finding suggests that, in elite controllers, immune activation is detrimental and leads to CD4+ T cell loss, despite suppressed plasma viral load, and that bacterial translocation may be the activating factor.
Marchetti et al. [32] investigated bacterial translocation in patients on highly active antiretroviral therapy (HAART). All patients on HAART had lower plasma levels of LPS than untreated control patients. As defined by blood CD4+ T cell reconstitution, therapy success was associated with even lower LPS levels. Patients who did not show T cell recovery despite suppressed HIV RNA had more bacterial translocation as quantified by plasma LPS than patients who responded immunologically and virologically to HAART. This means that in both groups with suppressed viral loads-either in elite controllers or in HAART-treated patients-low-level microbial translocation still occurs and seems to be associated with lower CD4+ T cell counts.
In support of the link between bacterial translocation and HIV pathogenesis, Ancuta et al. [1] found higher plasma LPS levels in patients with HIV-associated dementia than in HIV-positive patients without neurocognitive impairment. They proposed LPS-mediated monocyte activation and trafficking to the brain as the underlying mechanisms of this association between LPS and dementia. As supporting evidence, they showed upregulation of activation markers on monocytes and increases of soluble CD14, interleukin (IL)-6, and CCL2 in the plasma of HIV-infected patients.
To further investigate the effects of bacterial translocation on immune activation, Gregson et al. [16] compared plasma LPS levels in HIV-infected individuals to HIVnegative patients with active colitis, either colitis ulcerosa or morbus Crohn. All groups had similarly elevated LPS levels. However, colitis usually shows a fluctuating course: the gastrointestinal barrier, in fact, is only affected during an inflammatory phase but is relatively intact between flareups. In contrast, HIV-infected patients seem to experience constant bacterial translocation and immune activation.
However, factors other than bacterial translocation are thought to contribute to sustained immune activation. In particular, Gregson et al. reported that the activated phenotype of NK cells seen in their cohort of HIV-positive patients was linked to the plasma viral load and not to plasma LPS. Strikingly, the colitis patients, which had LPS levels as high as the HIV-positive patients, showed only low numbers of activated CD8+ T cells, indicating that high levels of plasma LPS alone do not cause activation of CD8+ T cells.
A study in patients undergoing interruption of antiretroviral therapy [44] supports the notion that CD8+ T cell activation not only depends on plasma LPS. In the first 6 weeks after stopping HAART, LPS levels remained unchanged, whereas percentages of activated blood CD8+ T cells increased. Only later did plasma LPS levels rise, but still no association with activated CD8+ T cells was detected, perhaps because the study examined a relatively small population. Interestingly, the delayed onset of LPS increase after treatment interruption mirrors the initial findings of Brenchely et al. [7] , which also showed that, for LPS to increase, some time of sustained viral replication was required. Plasma LPS levels were similar in patients with acute HIV infection and in healthy control subjects. A possible explanation is that, initially, systemically circulating LPS can be cleared, but, over time, this function is impaired. The treatment interruption study showed a negative correlation between changes of plasma LPS levels and endotoxin core antibodies (EndoCAb) in the early phase, when plasma LPS levels are controlled. Later on, this correlation is lost. They claimed that, initially, LPS is cleared by EndoCAb, and EndoCAb levels therefore decrease. After some time, clearance is no longer effective, due either to excessive microbial translocation or to inadequate B cell function.
In conclusion, there is universal agreement that heightened levels of circulating bacterial products correlate in general with immune activation in pathogenic lentiviral infections (Table 1) . However, careful interpretation is needed when deducing the mechanistic links between these events. A direct causative relation has not been established between heightened LPS levels and HIV disease progression. In an alternative explanation, microbial translocation may be an epiphenomenon of an activated and dysfunctional immune system. Also, what is the deficit in the GALT resulting in bacterial translocation? Recent studies propose a mechanism linking depletion of a subset of GALT effector site lymphocytes, namely Th17 cells, with breakdown of the gastrointestinal barrier. Such a link is a first step in explaining the relationships between HIV infection and GALT dysfunction.
Th17 cell help is essential for the integrity of the gastrointestinal barrier
Th17 cells are important for intestinal homeostasis (reviewed in [30] ). Briefly, this subset of CD4+ T cells is characterized by the production of IL-17 in response to stimulation, but they also secrete other cytokines, including tumor necrosis factor (TNF)-α, IL-1, IL-6, IL-21, and IL-22. Their strong proinflammatory properties are both beneficial and harmful. Initial animal studies identified Th17 cells as important mediators of autoimmune disease and tissue damage [24, 58] , yet, with their ability to recruit neutrophils [57] , they also are important for controlling infections by bacteria and fungi [18-20, 22, 31, 56] . Furthermore, Th17 cells are involved in epithelial regeneration [5] . They stimulate production of defensins and mucin [11, 53] , and they induce the expression of claudins [23] , which are components of epithelial tight junctions. Finally, IL-22, an important Th17 cytokine, increases the production of LPS binding protein (LBP) in the liver [55] . Considering the massive CD4+ T cell depletion in the lamina propria after HIV infection, it is reasonable to assume that Th17 cells are also depleted by HIV. And with their multiple functions in controlling epithelial integrity and microbial invasion, their loss likely affects the integrity of the gastrointestinal barrier.
While Th17 cells are permissive to HIV infection in vitro, they do not appear to be the preferential targets of HIV [8] nor of SIV [9] . Infection rates are similar in all CD4+ T cells, irrespective of Th17 or Th1 differentiation. Nevertheless, in acutely SIV-infected rhesus macaques, the intestinal Th17 responses seem to be afflicted more than the Th1 response. Checchinato et al. [9] found that the percentage of IL-17-producing cells, as related to all intestinal CD4+ T cells, was much lower, whereas the percentage of interferon-γ-producing cells was much greater than in healthy animals. Relative numbers, however, do not take into account the massive reduction of absolute CD4+ T cell numbers in the gut during acute SIV infection. Even though relative numbers of Th1 cells may be increased, the absolute numbers are still strongly reduced. It is difficult to judge the importance of relative differences between Th17 and Th1 responses in light of the overall loss of lymphocytes.
Brenchley et al. [8] further investigated the effects of HIV infection on T cell subsets at different mucosal surfaces and compared T cell responses in lung and gut. In contrast to results from bronchoalveolar lavage samples, they found a preferential depletion of IL-17-producing CD4+ T cells in the gut of HIV-infected humans. This result indicates that HIV infection especially reduces the intestinal Th17 function. In contrast to reports in humans, in SIV-infected sooty mangabeys, the relative numbers of IL-17+ CD4+ T cells in the gut are similar to those in uninfected animals. The authors linked this intact Th17 function in SIV-infected sooty mangabeys with their nonpathogenic phenotype. Again, one should be careful in interpreting relative cell numbers from the gut because of the overall depletion of CD4+ T cells.
Still, the data from both these studies suggest that the intestinal Th17 response is diminished during lentiviral infection, probably due to depletion or dysfunction of these In conclusion, these studies propose a model in which HIV/ SIV-mediated Th17 depletion from GALT effector sites impairs the gastrointestinal barrier. This, in turn, leads to translocation of intestinal microbes or microbial products, which then contribute to immune activation (Fig. 1) . However, we must be aware that no definitive experimental proof links Th17 dysfunction and elevated LPS levels. Increased intestinal Salmonella invasion after SIV infection is an intriguing hint but not the same as continuous translocation of harmless commensal bacteria. In Cecchinato et al. [9] , for example, no correlation between LPS levels and GALT Th17 cell numbers was found in SIV-infected macaques. Nevertheless, Th17 cells probably are important in overall immunodeficiency. Recently, a defect in Th17 differentiation in patients with autosomal dominant hyper-Ig-E syndrome [36] was identified. Hyper-Ig-E syndrome is characterized by Candida infections, recurring pneumonia, skin abscesses, and lymphomas-a clinical picture reminiscent of AIDS. However, no data exist on the integrity of the gastrointestinal barrier and bacterial translocation in these patients.
A disturbed gastrointestinal barrier may have negative effects on the immune system While circulating microbial products correlate well with activation markers on immune cells, the exact connection between these two phenomena is not clear. Does immune activation render the immune system so dysfunctional that it can no longer control bacterial translocation, or do the circulating bacteria and bacterial components activate the immune system and thereby contribute to the progressive immunodeficiency observed in HIV? Both possibilities likely coexist, leading to a vicious circle in which one factor triggers the other one. In any case, sustained immune activation has negative effects on T cell function and survival. For one, sustained activation provides a large pool of activated CD4+ T cells, which are optimal viral targets since HIV more efficiently infects and replicates in activated CD4+ T cells [12] . However, in most of the above studies, no positive association between plasma viral load and LPS was found [7, 44] . This is not surprising since many other factors besides overall activation status can influence viral load (e.g., HIV-specific immune responses, chemokine levels, and viral fitness).
In addition to providing a continuous reservoir of optimally activated HIV target cells, microbial products may initiate activation-induced cell death. An innovative study by Bourgeois et al. [4] in mice showed that naive CD4+ T cells are especially affected by activation-induced cell death from gut antigens. While investigating peripheral T cell dynamics after thymic ablation, they found a substantial decay in naive CD4+ T cells, while CD8+ T cell counts remained relatively stable. As the cause of CD4 + T cell activation and subsequent activation-induced death of naive cells, they identified translocation of microbial products from the gut. Indeed, the mice had higher levels of LBP, an acute-phase protein produced in the liver after exposure to LPS. Notably, in transfer experiments, they established that those CD4+ T cells reactive to gut microbes and involved in intestinal inflammation were lost specifically. Induction of intestinal inflammation by transfer of T cells reactive to gut microbes is an established tool in colitis research [29] . Naive CD4+ T cells depleted of CD25 high cells are transferred into immunodeficient mice; there, they proliferate and respond to intestinal antigens. Bourgeois et al. [4] found that CD4+ T cells from donor mice with bacterial translocation could no longer induce colitis in the recipient mice. Because of the antigen recognition and activation mechanisms in CD4+ T cells, these cells may be especially prone to effects from microbial translocation. Microbial products circulate in the extracellular compartment and are taken up by antigen-presenting cells for processing and presentation on major histocompatibility (MHC) class II molecules. Thereby, CD4+ T cells (i.e., those cells recognizing antigen in the context of MHC II) but not CD8+ T cells are activated and die.
HIV infection likely influences other immune cells in the GALT. For example, T regulatory cells (Tregs) are also affected. Tregs are abundant in the intestinal mucosa and are involved in maintaining a healthy balance between tolerance and immune control of gut microbes. Highly viremic SIVinfected macaques have more mucosal Tregs than animals with low viral loads [3] . These numerous Tregs may contribute to a less efficient SIV-specific immune response and consecutively to increased SIV loads. However, this hypothesis is controversial. Another study showed that inhibiting Treg function with a blocking antibody to CTLA-4 increased SIV replication, particularly at mucosal sites [10] . This study suggests that Tregs are protective by reducing immune activation and viral replication. Thus, increased Treg numbers in highly Fig. 1 HIV infection depletes lymphocytes, including Th17 cells, from the GALT effector sites. Th17 cells are essential in maintaining an intact gastrointestinal barrier against gut microbes by producing cytokines that are essential for epithelial regeneration and neutrophil recruitment. In HIVpositive individuals, circulating microbial products can be detected, and these levels correlate with immune activation Fig. 2 Microbial translocation and ensuing immune activation can damage the immune system and contribute to HIV pathogenesis. By increasing numbers of activated cells, which are preferentially infected, microbial translocation can increase viral replication. Furthermore, activated cells are prone to activation-induced cell death, and immune reconstitution is limited due to fibrosis of the lymphatic tissue. Other immune cells, such as macrophages or γδ T cells, also are negatively affected by lentiviral infection and may be dysfunctional. Epithelial disturbance is also observed in HIV infection viremic macaques may represent a negative regulatory feedback mechanism.
The GALT contains many cell types besides classical CD4+ T cells (e.g., plasma cells, dendritic cells, monocytes, or γδ T cells). Little is known about their fates during chronic lentiviral infection. Some studies suggest that they may be essential for limiting microbial translocation. In addition to depletion of Th17 cells, Brenchley et al. [8] also noted loss of myelomonocytic cells in the GALT of HIVinfected individuals. These myelomonocytic cells, which include granulocytes, macrophages, and dendritic cells, are essential for killing and phagocytosis of gut microbes, and for orchestrating an adaptive immune response. Another hint for the involvement of additional GALT cells in controlling microbial translocation comes from one of the nonpathogenic SIV models: sooty mangabeys, which do not show prolonged systemic LPS increases despite GALT CD4+ T cell depletion, have astoundingly high numbers of γδ T cells [7] . γδ T cells build an interface between innate and adaptive immunity and are essential for immune function at mucosal surfaces [38] . Therefore, they may have a protective effect on integrity of the intestinal barrier and may limit bacterial translocation. Compared to humans, sooty mangabeys have higher numbers of γδ T cells, and their γδ T cell response to bacterial antigens is even enhanced [37] after SIV infection. In contrast, in HIVinfected humans, γδ T cell counts are lower, and the cells are anergic to stimulation with mycobacterial antigens [45] .
HIV infection also interferes with stromal and epithelial cells of the intestinal mucosa. During acute SIV infection, massive apoptosis occurs in the gut epithelium [27] . Proinflammatory genes are upregulated, and genes responsible for epithelial regeneration and digestive/metabolic functions are downregulated [47] . Notably, in chronic infection, a proinflammatory milieu marked by upregulation of IL-6 and STAT3 persists [39] , and mucosal IL-2, IL-4, and TNF-α are increased, leading to increased epithelial permeability [13] . Intestinal inflammation and epithelial apoptosis not only impairs the gastrointestinal barrier, chronic inflammation also has negative effects on overall tissue architecture. GALT tissue from HIV-infected patients shows marked fibrosis, and the amount of collagen deposition is even higher than in other lymphatic organs [14] . In lymph nodes, intense fibrosis correlates with low CD4+ T cell counts and poor T cell reconstitution under HAART [49, 50] , and the same very likely applies to GALT fibrosis. This observation explains the slow and poor reconstitution of GALT lymphocytes under HAART, despite suppression of the local mucosal inflammation and permeability changes mediated by successful antiretroviral treatment [13] .
In summary, accumulating data indicate that HIV causes a profound and complex disturbance of the mucosal immune function. The detrimental effects of HIV are not limited to CD4+ T cells. In chronic HIV infection, disturbed GALT function and microbial translocation are accompanied by an incessant vicious circle of immune activation and inflammation with deleterious consequences on viral replication, T cell and epithelial cell death, and dysfunction of multiple additional cells (Fig. 2) .
Conclusions
The GALT is one of the major organs affected by HIV infection. Viral replication and T cell loss are even more pronounced in the intestinal lamina propria than in other lymphoid tissues. Furthermore, in chronic HIV infection, a poorly controlled translocation of bacterial products (e.g., LPS) occurs and correlates with immune activation markers, which in turn are associated with disease progression. Recently, a handful of studies identified the critical role of Th17 cells in this process. During pathogenic lentiviral infections, Th17 function in the GALT is reduced and invasion of gut bacteria-directly shown so far only with Salmonella-is increased.
However, many questions remain. Cause and effect relations in this circle of immune dysfunction and bacterial translocation are difficult to pin down. Consequently, one cannot predict if reduction of bacterial translocation or immune activation would be a beneficial therapeutic approach. Studies with compounds blocking immune activation so far did not show positive effects [25, 48] , maybe due to a general immunosuppressive effect of these drugs. Despite reduced immune activation, which may prevent further deterioration of immune functions, such drugs will also reduce immune responses directed against the virus. The optimal therapy should reduce the damaging general activation of immune cells, boost HIVspecific immune responses, and activate antimicrobial defenses at mucosal surfaces to reduce translocation of gut microbes.
